Pluri Inc. (PLUR), a clinical-stage biotechnology company focused on developing novel cell therapy products, is currently trading at $3.35, marking a 1.33% decline in recent trading sessions. This analysis reviews key technical levels, prevailing market context, and potential price scenarios for the stock, with no investment recommendations included. Key levels to monitor in upcoming sessions include a near-term support floor at $3.18 and a near-term resistance ceiling at $3.52, both of which ha
PLUR Stock Analysis: Pluri Inc. drops 1.33% to $3.35, key support levels assessed
PLUR - Stock Analysis
4000 Comments
1073 Likes
1
Faun
Active Contributor
2 hours ago
{协议答案}
👍 58
Reply
2
Genevee
Daily Reader
5 hours ago
{协议答案}
👍 200
Reply
3
Caanan
Loyal User
1 day ago
{协议答案}
👍 282
Reply
4
Adelso
Elite Member
1 day ago
{协议答案}
👍 285
Reply
5
Teyo
Influential Reader
2 days ago
{协议答案}
👍 241
Reply
Disclaimer: Not investment advice. For informational purposes only. Past performance does not guarantee future results. Trading involves substantial risk of loss.